IPO Boosts Avalyn
Avalyn Pharma Secures IPO Funds, Extends Operations to 2029 Amidst Clinical Program Progress
Anonymous
Avalyn Pharma reported first-quarter 2026 results with a net loss of $26.9 million and $123.1 million in cash, cash equivalents, and marketable securities as of March 31, 2026, while R&D and G&A rose year over year as clinical programs progressed and staffing increased. In May 2026, the company completed an upsized IPO that raised about $345.0 million in gross proceeds and said the combined funding is expected to support operations into 2029. Clinically, Avalyn said its AP01 inhaled pirfenidone MIST Phase 2b trial is on track to finish enrollment in mid-2026, with topline results expected in H2 2027 and additional long-term open-label extension tolerability data planned for presentation at EULAR. For AP02, its inhaled nintedanib AURA Phase 2 trial is underway in idiopathic pulmonary fibrosis, with topline data anticipated by the end of 2027. The company also reiterated that it plans to initiate AP03, an inhaled fixed-dose combination of nintedanib and pirfenidone, with Phase 1 starting by the end of 2026.
Key Points
1
Avalyn reported that total assets were $135.7 million and total liabilities were $27.7 million as of March 31, 2026, providing additional context to its liquidity position alongside the $123.1 million cash/cash equivalents/marketable securities.
2
Management broke down Q1 2026 operating costs, reporting R&D of $22.9 million (vs. $15.3 million in Q1 2025) and G&A of $5.0 million (vs. $3.4 million), attributing the year-over-year increases to progression of AP01 and AP02 and personnel-related expenses.
3
For AP01’s MIST Phase 2b trial, Avalyn specified the program design as enrolling 375 patients over a 52-week period; it also said EULAR will feature long-term open-label extension tolerability data “out to 48 months” from a compassionate use PPF cohort.
4
For AP02’s AURA Phase 2 study, Avalyn gave additional enrollment/launch details: it is a 160-patient, 12-week trial, and it noted that the “first patient [was] dosed in March 2026,” with topline data expected in late 2027.
5
Avalyn CEO Lyn Baranowski emphasized the company’s inhaled-nebulization strategy and tolerability thesis, saying the IPO “provid[es] the capital to advance three potentially paradigm-shifting programs” and that improved tolerability “can unlock the potential for extended duration of treatment and clinical benefit.”
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
19
Reach
29
A
AnonymousAuthor
